**Background of GPD2 Antibody**
Glycerol-3-phosphate dehydrogenase 2 (GPD2) is a mitochondrial enzyme critical for the glycerol phosphate shuttle, a metabolic pathway facilitating the transfer of reducing equivalents (NADH) from the cytoplasm into mitochondria for ATP production. This enzyme catalyzes the conversion of glycerol-3-phosphate to dihydroxyacetone phosphate, linking carbohydrate and lipid metabolism. Dysregulation of GPD2 has been implicated in metabolic disorders, including diabetes, obesity, and non-alcoholic fatty liver disease, due to its role in energy homeostasis.
GPD2 antibodies are essential tools for studying the enzyme's expression, localization, and function in cellular and disease contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess GPD2 protein levels in tissues or cell lines. Recent research highlights GPD2's potential involvement in cancer, where altered expression may influence tumor cell proliferation and survival via metabolic reprogramming.
These antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes of human or murine GPD2. Their validation includes specificity checks using knockout models or siRNA-mediated silencing. By enabling precise detection of GPD2. these antibodies support investigations into metabolic diseases, cancer biology, and therapeutic targeting of mitochondrial energetics.